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I Executive summary
QQ Responses to the emergence of new psychoactive 
substances (NPS) across Europe have largely been 
regulatory. However, findings from this study show that 
health- and drug-related interventions have emerged in 
response to evidence of harms associated with NPS use 
in some user groups and settings across Europe.
QQ Interventions identified and recommended in this study 
are largely based upon existing responses to drug use. 
Although limited, approaches have been adapted to 
reflect unique user group needs, the structural, cultural 
and social contexts of use, and new opportunities for the 
engagement of user groups and delivery of services.
QQ A number of key groups are considered to be at greater risk 
of NPS use and related harms. This includes, but is not 
limited to, participants in nightlife, men who have sex with 
men (MSM), people in custodial settings, young people and 
people who inject drugs. Such groups can be accessed 
across a range of settings including low-threshold services, 
specialist treatment, sexual health services, nightlife 
settings, schools, prisons and other custodial settings.
QQ Good practice guidelines and recommendations for 
responding to NPS tend to reflect evidence-based 
responses to harms associated with the use of established 
drugs, and include drug education, professional training 
and awareness-raising activities for health professionals, 
and low-threshold services such as needle and syringe 
exchange programmes (EMCDDA, 2015b).
QQ Given a lack of specific data on the use, nature, harms 
and effectiveness of various responses to NPS use, 
existing effective approaches in reducing drug use and 
associated harms across settings should be adapted to 
incorporate NPS. This assumes that existing responses 
to drug use are already effective and delivered to a high 
standard, but it is clear that this is not always the case. 
Reference should always be made to authoritative 
guidelines and quality standards.
QQ Although innovation should be encouraged, approaches 
that have already been shown to be ineffective or 
unhelpful are unlikely to be improved with adaption.
QQ Responses to NPS use must adapt to the unique harms and 
needs experienced by some members of some user groups, 
and the content and delivery of existing interventions may 
need to be carefully adapted. A professionally competent 
workforce with the required skills is needed to adapt and 
support health responses to NPS use, and needs 
assessments can assist in adapting existing approaches.
QQ There currently appears to be an overall limited demand 
for specialist treatment for NPS in Europe, although some 
specialist services have been developed in Member 
States where a need for such services was identified. 
However, in some Member States the lack of drug 
services that target NPS users and ‘recreational’ drug 
users in general has been reported to explain the low 
demand observed within existing treatment services. 
Multi-disciplinary approaches offer a useful way of 
engaging vulnerable groups who may not come into 
contact with traditional drug services (e.g. engaging MSM 
who practise ‘chemsex’ via sexual health services). 
Joined-up working across services is considered 
important, but can be difficult to realise and implement.
QQ Cultural competence (an understanding of how (sub) 
cultural issues influence patterns of drug use and 
associated harms) is required to improve service 
engagement and uptake. This includes services being 
accessible and welcoming, but staff may also require 
training to develop the necessary cultural competencies 
to work with diverse groups of NPS users, who may not 
previously have presented to drug services.
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I Introduction
The emergence of NPS over the last decade poses an 
important challenge to drug policy (UNODC, 2013). While 
prevalence levels of NPS use remain low in the general 
European population, there are important concerns with more 
problematic forms of use and harms in particular risk groups 
across different health and social settings. Important public 
health issues have arisen as a consequence of their use, 
although the real extent of these harms across Europe remains 
unknown. Initial responses to NPS in Europe have largely been 
regulatory, focusing on their supply using legislative tools 
(EMCDDA, 2015a) but, as the phenomenon evolves, it has 
increasingly become a priority to formulate and implement 
effective public health responses. Yet, while information on 
and our understanding of the availability and use of NPS have 
increased, there are still considerable knowledge gaps in 
current practices and even in the challenges and needs of 
European health professionals who are responding to the use 
of and harms caused by these novel substances.
Therefore, this short report first provides an overview of the 
current situation in terms of NPS use and harms across 
Europe. It then reviews and discusses the available health- and 
drug-related interventions to reduce and prevent the use and 
potential harms of NPS, and the challenges posed to European 
health professionals by an increasingly diverse and dynamic 
drug market. Health- and drug-related interventions covered in 
this report include acute care in emergency settings, as well as 
drug treatment, harm reduction and prevention activities 
delivered over the internet and in various interventions settings 
such as schools, specialist treatment centres, low-threshold, 
nightlife, sexual health and custodial settings. 
I Methodology
To address this lack of evidence and information, a rapid 
review of the literature was conducted following a two-day 
consultation with a range of European experts working in a 
number of settings across Europe. Literature searches were 
conducted by both the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) and Liverpool John Moores 
University (LJMU) using a number of academic literature 
databases, hand-searching reference lists within documents 
and searching for grey literature on numerous organisations’ 
websites. In October 2015 the EMCDDA brought together a 
multidisciplinary expert panel comprising European health 
professionals and researchers (N=17) to explore the 
challenges, needs and best practice in responses to NPS in a 
variety of health and intervention settings (see p. 22 for the 
list of experts). The consultation provided a platform to 
identify current health and intervention responses, and to 
highlight key issues and challenges in planning and delivering 
health responses to NPS use and harms across Europe. 
In-depth notes taken throughout the consultation alongside 
the expert presentations were considered and reflected on 
when writing this report. Project descriptions, publications 
and any literature documenting the evidence base or 
guidelines that may underpin the various approaches taken 
within specific intervention settings were also requested.
For the purposes of this report, health- and drug-related 
interventions include acute care management, drug 
treatment, harm reduction and prevention activities. Adopting 
a socioecological approach to the promotion of health and 
well-being (McLeroy et al., 1988), the report emphasises both 
specialist individually targeted health responses and wider 
societal and community actions, and the relationships and 
interactions that link them all together. It is important to note 
that the high-risk groups focused on in this report are not 
exhaustive and other groups (e.g. patients experiencing 
mental ill health, sex workers, people who are vulnerably 
housed, looked after and accommodated children) may also 
be at increased risk of NPS-associated harms. In some cases 
the groups discussed in the report were presumed to be at 
high risk despite a lack of formal evidence.
Additionally, a settings-based approach was taken to draw 
attention to specific issues faced by a number of high-risk 
groups, by health professionals and the health and 
intervention responses that are available in these settings. 
High-risk user groups identified include: partygoers/nightlife 
attendees; individuals presenting to emergency departments; 
people in prison; existing problematic users and people who 
inject drugs (PWID); and MSM. Young people are also 
included, not necessarily because they are at greater risk 
from acute harms of NPS use but because use in this stage 
of development may establish future drug behaviours, may 
lead to more years of ill health, and they may not have 
developed the resources to ‘self-manage’ their drug use. 
Moreover, there has been heightened societal concern over 
the use of NPS by young people throughout Europe. Although 
a settings-based approach is taken, it is acknowledged that 
whilst these groups may be more likely to come into contact 
with services in particular settings, they could also present 
across a number of settings. See Figure 2 for a description of 
the settings and user groups included in this report.
In summary, this report is based on a rapid review of the 
literature, the conclusions of the two-day consultation and 
further project information provided by consultation 
participants. Case studies are presented and key issues in 
need of consideration when responding to the use and harms 
of NPS are discussed. It is intended that this information and 
the recommendations will be useful to practitioners working 
across a number of settings when planning and delivering 
NPS health and intervention responses.
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I Limitations
The targeted multi-source data collection approach used in this 
report is designed to explore emerging threats or developments 
in new areas where, by their very nature, existing literature is 
weak and restricted. It is understood that the information will be 
partial and incomplete. Whilst proving timely and valuable 
insights, the approach has obvious weaknesses based on the 
incompleteness of the information available. Therefore, 
interesting hypotheses can be generated for follow-up research, 
and a useful purpose is served by auditing the information 
available on the situation, but caution must be exercised in 
over-inferring from the data available. Results presented in this 
report are based on analysis and triangulation of the qualitative 
data sources described above. However, the limitations of 
reliance on qualitative data and expert opinion need to be 
acknowledged and caution applied in interpretation of results.
I Definition of NPS
Various definitions of NPS exist, although no formal definition 
is universally accepted. Some definitions refer to ‘novel’ 
psychoactive substances and some to ‘new’ psychoactive 
substances. For consistency with wider EMCDDA work, the 
latter is used in this report (abbreviated as NPS), but it is 
acknowledged that although these substances may be newly 
and recently created, some were synthesised many years ago 
with new evidence of sale and use. This report defines a NPS 
as ‘a new narcotic or psychotropic drug, in pure form or in 
preparation, that is not controlled by the 1961 United Nations 
Single Convention on Narcotic Drugs or the 1971 United 
Nations Convention on Psychotropic Substances, but which 
may pose a public health threat comparable to that posed by 
substances listed in these conventions’. These substances 
are psychoactive in that they stimulate or depress the central 
nervous system (Council Decision 2005/387/JHA).
Although a legal definition is provided here, it is also 
important to move beyond this (i.e. novelty of substances and 
international control) in order to focus additional attention on 
emerging drug issues and trends, new types of harm and 
newly emerging user groups. Therefore, the report sometimes 
refers to the use of drugs that are not legally classed as NPS 
but have a history of recreational use with new evidence of 
harm beginning to emerge (e.g. ketamine), and also a number 
of controlled substances used in similar settings and target 
groups, especially ‘club drugs’
Figure 1
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Figure 2
Relevant intervention settings (outer ring) where potential NPS-related harms and risk behaviours (middle ring) are 
reported by or observed among at-risk groups (inner ring)
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I Overview of the current situation and challenges
Concern surrounds the rapid emergence of NPS, their open 
sale, a lack of evidence on their effects and harms, and how 
to effectively respond (EMCDDA, 2015c; United Nations, 
2014). The number of new drugs being detected and seized 
across Europe continues to grow. In 2015 a total of 98 new 
substances were detected for the first time, bringing the 
number of new substances monitored to more than 560, of 
which 70 % were detected in the last five years (EMCDDA, 
2016d). These include synthetic cannabinoids, stimulants 
(including cathinones), hallucinogens and opioids that are 
designed to mimic the effects of established substances 
(see Figure 1). Whilst many of these substances tend to 
quickly disappear from the market and fail to diffuse, some, 
particularly synthetic cathinones such as mephedrone, are 
now prominent within illicit drug markets and recreational 
and problematic drug repertoires. European drug markets 
have therefore continued to evolve and diversify, with 
continued long-term and new patterns and trends of use 
(EMCDDA and Europol, 2016)
Estimating the prevalence of NPS use is challenging due to 
methodological and definitional inconsistencies, which also 
makes comparing national estimates difficult. The Flash 
Eurobarometer (European Commission, 2014) survey of 
drug use among young people aged 15–24 estimated that 
lifetime use of ‘legal highs’ (defined as new substances that 
imitate the effects of illicit drugs) was relatively low, with 
8 % reporting lifetime use and 3 % reporting use in the last 
year (European Commission, 2014). Comparing national 
survey results, the EMCDDA reported that last year 
prevalence of NPS use (not including ketamine and GHB) 
among young people aged 15–24 ranged from 9.7 % in 
Ireland to 0.2 % in Portugal. A number of non-
representative prevalence studies have also helped to 
establish use among key groups such as school students, 
partygoers, people in prison and existing injecting drug 
users (EMCDDA, 2015b). Thus, whilst the prevalence of 
NPS use in the general population is low compared to more 
established drugs such as cannabis and MDMA/ecstasy, it 
can be tentatively concluded that NPS use appears to be 
more important among some of these risk groups. When 
considering prevalence it is important to acknowledge that, 
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for most user groups, NPS are one component of 
polysubstance use, and they are generally added to 
existing drug repertoires rather than replacing (established) 
drugs that are already used (Sumnall et al., 2013). 
Moreover, users may experience NPS harms without 
meeting the diagnostic criteria for a substance use disorder 
or presenting to structured services, and their experience 
of NPS may change with age and the context of use.
There is a general lack of data on the public health and 
societal harms of NPS. However, there is increasing 
evidence of the association of NPS with hospital 
emergencies, acute adverse health consequences and 
some drug-induced deaths, although in many cases of 
fatal intoxication other substances had also been taken 
(EMCDDA, 2014a, 2014b, 2015a, 2015b). For example, 
unlike herbal cannabis, synthetic cannabinoids have been 
associated with strokes, and liver and kidney damage, and 
there are concerns that the use of these types of NPS may 
exacerbate psychiatric symptoms (Castaneto et al., 2014; 
Papanti et al., 2013). Similarly, mephedrone and other 
substituted cathinones have been associated with 
injection, compulsive use and social harms in some 
European Union (EU) countries (EMCDDA, 2015b). In 
some regions of Hungary, Romania and the United 
Kingdom there has been an increase in demand for 
treatment associated with the use of such substances. 
However, the number of deaths associated with the use of 
NPS and the number of individuals in treatment for NPS 
use is much smaller than for established drugs, which may 
reflect lower prevalence rates (EMCDDA, 2015b).
There are diverse legal and policy responses to NPS across 
Member States, and the Council of the EU is currently 
developing a model of regulation (EMCDDA, 2015a). These 
actions, and general drugs policy, may facilitate or limit the 
types of intervention that might be delivered. For example, 
whilst on-site drug checking is supported, or at least 
tolerated, by some governments, others have publicly 
opposed formally supporting and funding such work. 
Similarly, some countries provide full community 
equivalence of health services in custodial settings 
(including needle and syringe programmes), whilst others 
do not. It is also important to acknowledge the unintended 
secondary harms of drug policy, which may lead to the 
exclusion, stigmatisation and de-prioritisation of some user 
groups, including NPS users (e.g. UKDPC, 2010). 
The following sections of this report provide an overview of 
health and intervention responses in seven different 
intervention settings by highlighting key issues, evidence 
and challenges in planning and delivering health responses 
to NPS use and harms in these settings.
I School and family settings
Schools are the most common setting for the delivery of 
drug prevention and education in the EU (EMCDDA, 
2015b), and whilst there is a developing evidence base for 
effective approaches and programmes these activities 
tend to be focused on drugs such as cannabis, or target 
substance-related risk factors and harms in general 
(EMCDDA, 2015f; Faggiano et al., 2014).
As NPS prevalence in the school age population is low 
(European Commission, 2014), universal approaches, which 
target all students regardless of their level of risk of NPS use, 
are unlikely to be cost-effective. Accordingly, there is currently 
no evidence upon which to make recommendations for 
specific school-based NPS prevention activities. Whilst 
existing (and effective) prevention programmes may be 
adapted to include NPS (e.g. the online Australian Climate 
Schools: Ecstasy and Emerging Drugs Module currently being 
trialled by Champion et al., 2015) it is important that these are 
only delivered as part of a carefully monitored evaluation in 
order to assess the impact of the adaption and the 
effectiveness of the programme on the targeted behaviours. 
This is because, despite best intentions, many prevention 
programmes and approaches are ineffective (e.g. standalone 
mass media and information campaigns, fear arousal 
approaches, random drug testing), and may even have 
negative effects and lead to increased drug use or intention to 
use drugs because, for example, they may ‘normalise’ NPS 
use (i.e. they may give the impression that more people use 
NPS than actually do) or bring attention to behaviours that 
might otherwise have been avoided (e.g. by raising awareness 
of the use of synthetic cannabinoid receptor agonists (SCRAs) 
as a substitute for the relatively less harmful cannabis). 
Furthermore, there are important ethical concerns about 
delivering ineffective or harmful programmes instead of those 
that are likely to lead to positive changes in behaviour. 
Resources such as the European Drug Prevention Quality 
Standards (Brotherhood and Sumnall, 2011) and other tools 
(UNODC, 2013) might be useful in the development and 
refinement of NPS-related prevention activities.
It is therefore recommended that school-based NPS-related 
prevention activities should only be delivered as part of 
generic prevention programmes for which there is evidence 
of effectiveness (EMCDDA, 2015b; Faggiano et al., 2014; 
UNODC, 2013). Such approaches include interactive skills 
training, classroom management activities and school 
retention programmes, and might also include family 
components such as monitoring and supervision. If there is 
evidence of need (e.g. there have been local NPS-related 
incidents, or surveys suggest use is likely to be high in the 
locality), NPS-specific components might focus on providing 
accurate descriptive and injunctive norms (e.g. based on local 
data ‘very few people use NPS’; and ‘young people like you 
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say they don’t want to take risks with unknown NPS’). NPS 
education, including harm reduction, is most appropriate for 
those target groups and individuals who are either already 
using drugs, or at increased risk of use. Schools are also a 
suitable setting in which to deliver indicated and targeted 
prevention approaches, but the same considerations apply.
Teachers and other school staff may not have the skills 
required to assess NPS-related risk, respond to questions 
about NPS from students or deliver specific prevention 
activities, and therefore other organisations might be best 
placed to deliver these or to receive referrals in the school or 
community setting. It is important that the decision on 
which external providers and resources to use is carefully 
considered in order to ensure accuracy and objectivity, 
quality of delivery, the developmental and experiential 
relevance of the material covered, and coherence with the 
school’s wider approach to health and well-being.
I Nightlife settings
Individuals (commonly referred to as ‘partygoers’) 
participating in nightlife settings such as bars, pubs, 
nightclubs, discotheques and music festivals and events 
report high rates and frequency of drug use compared to 
the general population (EMCDDA, 2014b). Despite this, the 
overall use of NPS in nightlife settings is relatively low 
compared to traditional club drugs (Stephenson and 
Richardson, 2014). Even so, the use of drugs and alcohol in 
nightlife settings has been associated with an increased 
risk of a range of health and social harms such as injury, 
aggressive behaviour, unsafe/unwanted sex and driving 
under the influence (EMCDDA, 2006, 2012; Charlois, 
2009). In addition, acute and chronic health risks are 
commonly associated with the consumption of drugs of 
unknown content, strength and purity.
Nightlife settings are therefore relevant to developing an 
understanding and response to drug use (including NPS) and 
provide opportunities to target recreational and harmful drug 
use. A range of health responses to drug use and related 
harms have been applied to nightlife settings and include 
changes to the physical environment (e.g. chill out rooms, 
crowd control, ventilation), the provision of information, 
education, outreach, drug checking and crisis management 
(Charlois, 2009; EMCDDA, 2012; Brunt and Niesink, 2011; 
Valente et al., 2015). There are a growing number of examples 
of both on- and off-site drug checking services across Europe 
that provide chemical analysis of drugs submitted for testing 
by users (see boxes on ‘CHECK!N’ and ‘checkit!’, p. 9 for 
examples of on-site drug checking facilities and boxes on 
‘DIMS’ and ‘WEDINOS’, p. 10 for examples of off-site 
facilities). Such facilities are presented as an opportunity for 
CHeCK!N was established in Portugal in 2009 as a drug 
checking and harm reduction information platform. it 
carries out on-site analysis of NPS and more traditional 
drugs with the aim of promoting the health and safety of 
partygoers by providing safe and reliable information to 
users of psychoactive substances. in addition to practical 
interventions (such as testing equipment, condoms, 
alcohol breathalyser), CHeCK!N provide crisis 
management in the form of on-site counselling and advice 
for users experiencing psychological distress after 
ingesting drug/s. CHeCK!N also provides training and 
education to peers, staff in nightlife settings and health 
professionals working with at-risk groups. An evaluation of 
CHeCK!N at a festival in 2014 found that almost half of the 
drugs analysed (45 %) were not what users expected 
them to be. As a result, users’ drug-use intentions changed 
— 29 % reported intending not to consume the drug and 
71 % intending still to consume the drug but with the aim 
of searching for more information (10 %), taking a smaller 
dose (15 %) or not mixing it with other substances (30 %).
See: www.apdes.pt/en/services/health-harm-
reduction-human-rights/check!n.html
CHECK!N — APDES, Portugal
Operating in Vienna since 1997, the checkit! programme 
provides an on-site drug checking analysis in nightlife 
settings and provides users with a content analysis of 
their drugs, harm reduction information and counselling 
on the effects and dangers of psychoactive substances. 
The aim is to reduce drug-related harms and provide 
early warnings on potentially dangerous substances (or 
dangerous doses) that are in circulation. Although there 
are no recent evaluations of the programme, checkit! 
has previously issued alerts regarding the circulation of 
PMA/PMMA pills (eMCDDA, 2001). Furthermore, a 
recent review of the programme found that between 
2010 and 2014 there was a significant decrease in the 
number of users who expected NPS to be in their 
analysis (8.9 % in 2010; 0.8 % in 2014) and those who 
didn’t (10 % in 2010; 4.1 % in 2014), and overall there was 
a decrease in NPS presented at events attended by 
checkit! (19 % in 2010; 4.9 % in 2014) (Schmid, 2015).
See: www.checkyourdrugs.at
checkit!, Austria
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users to make an informed decision about their intended 
drug use, and some service providers also use the interaction 
to deliver personalised advice and harm reduction 
information, screening and brief intervention (TEDI, 2013). 
Data from testing may also be directed to policymakers and 
health and social welfare professionals, who may benefit 
from information on the nature of drugs in circulation in their 
operating geography. However, there is currently a lack of 
evidence on the effectiveness of drug checking in reducing 
drug use and related harms (including NPS), and there is a 
need for a better understanding of optimal content, framing 
and targeting of urgent communications about potentially 
harmful drugs. This is partly because users may not have 
the health literacy skills to access, understand and act upon 
the information in circulation, and because intoxication may 
make decisions around drugs more difficult. Furthermore, 
there is also a lack of standardisation of methods and 
analytical techniques, ranging from simple reagent testing 
kits targeted at consumers (e.g. Marquis/Mecke reagents) to 
more expensive and sophisticated equipment (e.g. infrared 
laser; high-performance liquid chromatography). These 
require specialist training for operation and interpretation 
and are the most adequate in identifying the chemical 
composition of psychoactive substances emerging on 
the market. 
The aims and impact of nightlife health responses are not 
always sufficiently defined or evaluated, and there is a lack 
of NPS-specific responses in nightlife settings (Pirona et 
al., 2016). However, health responses and interventions 
aimed at the use of established drugs and alcohol in 
nightlife settings are relevant and may be adapted to 
respond to NPS use and related harms (e.g. the EU Healthy 
Nightlife Toolbox and the EMCDDA Best practice portal 
entries on partygoers and nightlife).
I Sexual health settings
In recent years concern has surrounded the injection of 
stimulant drugs, including NPS, by small yet diverse groups 
of MSM in a number of European countries (Bladou, 2015; 
Csák, 2015; EMIS Network, 2010; EMCDDA, 2015b; PHE, 
2015; Stuart, 2015). Chemsex refers to the intentional use of 
drugs such as mephedrone, GHB/GBL and 
methamphetamine to enhance, sustain, disinhibit or 
facilitate sexual pleasure (Bourne et al., 2015a, 2015b). This 
practice is associated with both drug and sexual risk-taking 
behaviour (e.g. injecting known as ‘slamming’, unprotected 
sex, sex with multiple sexual partners, prolonged sexual 
sessions) and a range of harms including hospitalisations, 
overdose, sexually transmitted infections (STIs) and blood-
borne viruses (BBVs) such as human immunodeficiency 
virus (HIV) and hepatitis C virus (HCV); there are also 
implications for sexual consent (Bourne et al., 2015a, 2015b; 
Bracchi et al., 2015; Daskalopoulou et al., 2014a, 2014b; 
Grossman et al., 2015; McCall et al., 2015; PHE, 2015; 
Rawdah et al., 2015; Ruf et al., 2006; Stuart, 2013). Despite 
the risk of harm, it is important to note that not all users 
participating in such practices experience harm, and that by 
far not all MSM engage in this practice (Holt, 2014).
DiMS has been facilitating the testing of drugs for 
users since the 1990s. it was set up with the aim of 
preventing serious health hazards (e.g. adverse drug 
effects or unintentional overdoses) associated with 
using psychoactive substances, including NPS (Brunt 
and Niesink, 2011). users anonymously submit their 
drugs for testing and are asked a series of questions 
regarding their experience with the substance. By 
establishing this information exchange between users 
and the testing facilities, DiMS aims to quickly deliver 
prevention and harm reduction messages directly to 
users. Furthermore, DiMS contributes to monitoring 
the Dutch drug market and identifying newly emerging 
NPS and drug trends. Such monitoring allows it to 
extend its prevention activity to a range of substances 
and to issue national risk alerts on known dangerous 
substances or situations (Brunt and Niesink, 2011).
See: www.drugs-test.nl
Drugs Information Monitoring System 
(DIMS), the Netherlands
established in October 2013, WeDiNOS provides 
anonymous testing of NPS that are submitted to it. 
Between October 2014 and September 2015, 1 350 
samples were analysed, some of which were reported 
as new substances to the eMCDDA’s early Warning 
System (Wedinos, 2016). WeDiNOS also gathers 
information from users, such as symptoms experienced 
following the ingestion of drugs. This information 
enables the organisation to provide evidence-based 
harm reduction information and advice for users and 
also provides a means for identifying trends in use and 
toxic substances in circulation.
See: www.wedinos.org
Welsh Emerging Drugs and Identification 
of Novel Substances Project (WEDINOS),  
United Kingdom
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MSM who practise chemsex face a number of barriers to 
accessing services. These include stigma, a lack of cultural 
competence among traditional drug and sexual health 
service providers, MSM not self-identifying their drug use as 
problematic, a lack of awareness of available drug services 
among MSM, and a lack of provision of specific services for 
those who use chemsex drugs (Bourne et al., 2015a; McCall 
et al., 2015; PHE, 2015). A preference for MSM to engage 
with sexual health services and a need for combined sexual 
health and drug interventions has led to the development of 
joined-up services targeted at this population (Bourne et al., 
2015a; EMCDDA, 2015b; McCall et al., 2015; see boxes on 
‘56 Dean Street Sexual Health Clinic’ and ‘Burrell Street 
Sexual Health Centre’, p.11). With regard to reducing harms 
associated with sexual risk behaviour involved in chemsex, 
specialist support services for MSM with HIV may also be 
useful (e.g. associated with the interaction between 
recreational drugs and prescribed medication) and prevent 
the transmission of HIV and other STIs (Daskalopoulou, 
2014b). However, there is currently a lack of data to inform 
appropriate harm reduction services, and a lack of evaluation 
of the effectiveness of these approaches (Bourne et al., 
2015a). Guidance for clinicians in responding to the use and 
associated harms of club drugs for chemsex purposes is 
provided by the Novel Psychoactive Treatment: UK Network 
(NEPTUNE) (Abdulrahim et al., 2016; see box on ‘Guidance 
for substance use service staff working with MSM’, p. 12).
Regardless of the setting, the provision of clear, honest 
and non-judgemental advice on chemsex and information 
on how to manage potential harms should be delivered by 
culturally competent individuals (Abdulrahim and Bowden-
Jones, 2015; Bourne et al., 2015a, 2015b; PHE, 2015). 
Cultural competence in addressing chemsex is important, 
and the services presented here provide examples of 
culturally competent spaces for the provision of sex and 
drug services for MSM participating in chemsex. Given the 
lack of evaluation of current practice, it is important that 
research is undertaken into the effectiveness of such 
approaches in addressing the sexual, physical and mental 
health needs of MSM engaging in chemsex.
The Chelsea and Westminster Hospital NHS 
Foundation Trust, London, established the 56 Dean 
Street Sexual Health Clinic to respond to the specific 
needs of MSM (PHe, 2015; Stuart, 2013, 2015; 56 
Dean Street, 2014). Taking a partnership approach, it 
provides a range of services with the aim of 
addressing the public health harms associated with 
chemsex (e.g. HiV/HCV and STis) and the lifestyle/
well-being consequences of using (including 
injecting) drugs in such sexual contexts. Services 
provided include a needle and syringe programme, 
workshops and support for MSM addressing issues 
such as safe injecting and ‘sober’ sex, harm reduction 
advice and campaigns, sexual health advice and 
testing, community mobilisation and outreach and 
brief psychosocial one-to-one interventions (e.g. 
motivational interviewing) addressing goals around 
drug use and sexual behaviour. The service also 
provides information and training for healthcare 
providers working with MSM engaging in chemsex to 
familiarise them with this practice, the associated 
risks (e.g. HCV and HiV) and motivations for 
behaviour, whilst aiming to improve competencies in 
effectively communicating such risks and the 
importance of STi testing to clients. Although the 
service has yet to be evaluated, it provides an 
example of a partnership working to address the 
harms associated with drug use and sexual risk-
taking behaviour among MSM, and to improve the 
sexual and general well-being of clients.
See: www.chelwest.nhs.uk/services/hiv-sexual-
health/clinics/56-dean-street
56 Dean Street Sexual Health Clinic, 
United Kingdom
The Burrell Street Sexual Health Centre at guy’s and 
St Thomas’ NHS Foundation Trust, London, is an 
example of a specific harm reduction response to the 
injecting of club drugs for sexual purposes by MSM. 
Alongside the provision of sexual services such as 
advice, testing and treatment, the clinic has also 
developed, in collaboration with drug services, 
‘slamming kits’ containing colour-coded needles (to 
reduce the chances of using the wrong needle) and 
syringes labelled with measures for gHB/gBL (to 
reduce the risks of overdose). The kits are intended to 
encourage safe injecting among MSM engaging in 
chemsex (PHe, 2015;). PHe (2015) reports that 
distributing the kits has encouraged the use of other 
counselling and sexual health screening services at 
the clinic and has led to new diagnosis of HiV 
infections and STis among this population.
See: www.burrellstreet.co.uk
Burrell Street Sexual Health Centre, 
United Kingdom
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I Emergency and clinical services
It is difficult to estimate the number of NPS-related 
emergency presentations across Europe due to coding 
and data collection differences between and within 
countries. A recent study across 16 European Drug 
Emergencies Network (Euro-DEN) sentinel sites 
(see box on ‘Euro-DEN’, p. 13) between October 2013 
and September 2014 found that 5.6 % of 5 500 
presentations mentioned NPS. Whilst the potential 
long-term harms of most NPS are poorly understood, 
acute harm is typically encountered in presentations to 
emergency and other pre-hospital services (e.g. 
ambulances) (Wood et al., 2014a; Dines et al., 2015).
Despite limited understanding of the acute toxicity of 
many NPS, difficulties in identifying substances consumed 
(i.e. through self-report or toxicological screening), and the 
high proportion of polysubstance use, staff working in 
emergency settings have been required to develop 
treatment and best practice protocols in response to 
NPS-related presentations. Clinical management is 
QQ Services should aim to gain an understanding of local 
patterns of drug use (injecting, club drug and NPS 
use) among MSM through the use of surveys and 
other information sources.
QQ Staff within mainstream substance use services 
should be confident that they are responsive to the 
specific needs of MSM (e.g. sexual and mental health 
issues, issues of personal stigma, varying patterns of 
drug use). They should also be comfortable 
discussing sexual practices associated with drug use 
among MSM.
QQ MSM may not recognise their drug use as problematic. 
Staff should therefore be skilled in screening or 
supporting user self-identification of problematic drug 
use in appropriate ways.
QQ Services must be accessible to MSM (e.g. available 
outside normal working hours, dedicated chemsex/
MSM services housed in other accessible services).
QQ Joined-up working between substance use and sexual 
health services should be established and referral 
pathways developed.
QQ Needle and syringe programmes should be available 
within sexual health services. Programme staff should 
be aware that MSM may require different advice and 
equipment than is provided for opiate injectors (e.g. 
coloured needles).
QQ Staff should be aware that some MSM may have 
previous negative experience of substance use 
services and as such should be supported and 
supervised to explore such issues and develop their 
practice and services in accordance.
QQ Staff should receive training and support to develop 
their competencies in assessing, treating and referring 
MSM clients in a culturally sensitive and competent 
manner.
NEPTUNE overview and recommendations on club 
drug use among lesbian, gay, bisexual and transgender 
(LGBT) people
This document describes patterns of club drug use 
among LgBT populations, as reported in the literature. it 
examines at the factors that may impact on the use of 
substances and discusses drug-related and other harms.
The document also looks in some detail at the use of 
drugs in a sexual context and at the risks associated 
with a particular pattern of drug use and sexual 
behaviours, sometimes referred to as ‘chemsex’, that 
have been particularly associated with risk and harm. 
The document addresses treatment responses to club 
drug use for MSM and is intended to guide improved 
service and treatment planning.
See: Abdulrahim, D., Whiteley, C., Moncrieff, M. and 
Bowden-Jones, O. (2016), Club drug use among lesbian, 
gay, bisexual and trans (LgBT) people, Novel 
Psychoactive Treatment uK Network (NePTuNe), 
London. Available online at: neptune-clinical-guidance.
co.uk/wp-content/uploads/2016/02/neptune-club-
drug-use-among-lgbt-people.pdf.
Guidance for substance use service staff working with MSM (PHE, 2015)
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generally orientated towards providing symptomatic care, 
as much NPS toxicity is likely to be similar to that produced 
by better characterised drugs in equivalent 
pharmacological classes (see box on NEPTUNE guidelines, 
p. 16; Abdulrahim and Bowden-Jones, 2015). However, 
there are notable exceptions that illustrate gaps in clinical 
understanding. The dissociative methoxetamine, for 
example, unlike the more popular ketamine, is associated 
with cerebellar toxicity (Shields et al., 2012); whilst, unlike 
cannabis, presentations associated with SCRAs have 
included ischaemic stroke and acute kidney injury (Lovett 
et al., 2015). National poison centres are useful sources of 
expertise and advice, and for more frequently encountered 
NPS may provide an assessment of the hazards of a 
specific exposure, whether hospital referral is needed and 
the specific management required (Wood et al., 2014b).
Whilst most cases will be discharged within a few hours of 
presentation, there may be opportunities for medical staff 
to provide screening, brief advice and referrals to 
community support (EMCDDA, 2016b). In the busy 
emergency environment this may not always be possible, 
but the salience of acute care may mean that users are 
receptive to such interventions, and they may not 
otherwise come into contact with drug services. 
Opportunities for emergency care and support are not just 
limited to hospital settings. On-site medical support plays 
an important role in multidisciplinary outreach responses 
in nightlife and festival settings (see section on ‘Nightlife 
settings’, p. 9), and guidelines have been developed that 
aim to improve pre-hospital management and 
identification of individuals who require immediate 
hospital assessment by nightlife medics (Euro-DEN, 2015).
I Specialised treatment settings
Due to differences in NPS uptake and markets there are 
currently no comparable EU-wide estimates of problem or 
high-risk NPS use or presentations to treatment services 
where NPS, except synthetic cathinones, have been 
identified as the primary problematic drug. However, the 
EMCDDA reports treatment demand for a limited number of 
drugs of relevance regarding emerging trends and novel 
drugs in some countries. Overall, demand for specialist 
treatment remains low and represents less than 2 % of all 
clients entering treatment in Europe. Only the United 
Kingdom (1 266 clients) and Poland (321 clients) report 
noticeable figures for treatment demands related to 
problems associated with synthetic cathinones, 
representing between 10 % and 30 % of all clients entering 
treatment for stimulant-related problems in these two 
countries. GHB- and GBL-related treatment demands are 
observed mostly in the Netherlands and the United 
Kingdom, while the number of treatment demands 
associated with ketamine-related problems is low across 
Europe (EMCDDA, 2016d; see Table 1). With the exception 
Approved by the uK Department of Health and 
commissioned by Public Health england, the National 
Poisons information Service (NPiS) provides expert 
advice on all aspects (e.g. diagnosis, treatment and 
care) of acute and chronic poisoning as a result of 
exposure to a range of substances, including 
established drugs and NPS. information is provided via 
the NPiS’s online resource TOXBASe and by 
telephone. it provides healthcare professionals with 
rapid evidence-based advice to facilitate the clinical 
management of patients and others with suspected or 
confirmed poisoning and those who are (or may be) 
exposed to medicines or other potential poisons 
during pregnancy. in cases where toxicity is low, NPiS 
provides advice that aims to minimise unnecessary 
hospital attendances and admissions.
See: www.npis.org/index.html and www.toxbase.org
National Poisons Information Service, 
United Kingdom
The euro-DeN project was funded by the european 
Commission and has developed a network of 16 
sentinel sites in 10 eu countries. The network 
gathered, critically assessed, and analysed data on 
admissions to emergency departments with acute 
toxicity associated with the use of drugs (including 
NPS). in addition, the project aimed to improve the 
recognition and assessment of acute drug toxicity by 
providing training for staff working in recreational 
settings. During a 12-month data collection period 
(October 2013 to September 2014) the euro-DeN 
centres recorded over 5 500 presentations to 
emergency departments with acute drug toxicity. The 
network also produced guidelines for nightlife staff on 
when to call emergency services for unwell drug users.
See: www.emcdda.europa.eu/best-practice#view-
answer18
European Drug Emergencies Network 
(Euro-DEN)
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of groups identified elsewhere in the report it is currently 
unknown whether the NPS user population presenting at 
European treatment services differs from that of the 
traditional treatment client base, thus justifying different 
responses. Users of NPS may therefore require support for 
additional needs associated with (but not limited to) 
polydrug use, physical and mental ill health, offending 
behaviour, housing and employment problems, injecting 
behaviour and sexual health concerns.
Structured (community or inpatient) drug treatment 
responses to NPS are not expected to substantially differ 
from those offered to clients using drugs from similar classes, 
and in general it is recommended that existing high-quality 
evidence-based guidelines and quality standards for drug 
treatment are adhered to (e.g. Council of the European Union, 
2015; EMCDDA, 2016a; UNODC and WHO, 2008; WHO, 
2010). Unlike drugs such as opiates, there are currently no 
maintenance or substitute pharmacotherapies available for 
NPS and, with the exception of GHB/GBL (Kamal et al., 2013; 
TOXBASE UK guidelines, see boxes on ‘National Poisons 
Information Service’, p. 13 and  ‘GHB treatment at the 
Novadic-Kentron institute’, p. 17), there are few 
recommendations for specific pharmacological management 
of withdrawal. However, pharmacotherapies may be 
appropriate for symptom relief upon discontinuation.
TABLe 1
All clients entering specialist treatment for NPS-related problems as their primary drug in 28 Member States, Turkey and 
Norway (2014 data or latest data available)
Country Year
Synthetic 
cathinones
All 
stimulants
GHB/GBL
All hypnotics 
and sedatives
Ketamines
All 
hallucinogens
All clients 
with known 
primary drug
Belgium 2014 0 1 229 0 787 0 26 10 702
Bulgaria 2014 0 87 0 49 0 0 1 804
Czech Republic 2014 0 7 038 64 7 10 090
Denmark 2011 371 69 5 3 779
Germany 2014 13 664 1 754 133 85 026
Estonia 2014 12 5 281
Ireland 2014 35 152 1 1 065 1 5 9 523
Greece 2014 0 23 0 128 0 1 4 697
Spain 2013 1 923 0 1 175 70 120 51 946
France 2014 30 486 16 849 53 206 41 362
Croatia 2014 0 132 0 116 0 4 7 812
Italy 2014 266 9 298 11 80 51 224
Cyprus 2014 48 1 4 1 068
Latvia 2014 3 126 1 23 0 6 826
Lithuania 2014 0 81 0 32 0 4 2 159
Luxembourg 2014 1 1 271
Hungary 2014 0 894 0 170 0 244 4 688
Malta 2014 29 2 3 1 755
Netherlands 2014 0 773 302 592 7 11 10 631
Austria 2014 6 190 0 94 0 5 3 422
Poland 2014 321 2 635 11 287 3 11 7 186
Portugal 2014 0 6 0 14 0 4 2 858
Romania 2014 2 21 0 131 2 4 2 617
Slovenia 2014 3 21 419
Slovakia 2014 0 1 064 0 78 0 1 2 483
Finland 2014 0 91 1 43 0 0 644
Sweden 2014 9 2 505 5 3 659 0 302 33 506
United Kingdom 2014 1 266 4 889 119 2 312 273 345 97 068
Turkey 2014 139 50 1 1 10 630
Norway 2014 1 147 779 39 8 581
Source: EMCDDA Statistical Bulletin 2016, treatment demand data tables (www.emcdda.europa.eu/data/stats2016)
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The NEPTUNE guidelines (Abdulrahim and Bowden-Jones, 
2015; see box on NEPTUNE guidelines, p. 16) suggest that 
the nature and intensity of the treatment offered should be 
related to the severity of the NPS problem, with an 
assessment of the health and other consequences of use. 
Some clients presenting to treatment services may benefit 
from low-intensity brief interventions based on general or 
tailored advice (e.g. using the FRAMES model), and even 
those showing NPS-related harm may benefit most from 
self-help approaches rather than referral to a structured 
intervention. Where problematic or high-risk NPS use has 
been identified, individual/group-based behavioural and 
psychosocial approaches (e.g. cognitive behavioural 
therapy, motivational interviewing, community 
reinforcement and contingency management) or formal 
psychological therapies, delivered as part of a staged or 
stepped care approach, may be effective (EMCDDA, 
2016a; Abdulrahim and Bowden-Jones, 2015). Therefore, 
a thorough assessment of NPS use, the consequences of 
use and related needs is essential. Relapse prevention 
techniques are also recommended according to 
individual needs.
Structural barriers and treatment system deficiencies may 
prevent users of NPS accessing services and obtaining 
appropriate treatment. Many of these factors are likely to be 
similar to those related to treatment-seeking for other drugs 
(WHO, 2010), although some are unique to NPS. Few EU 
countries report an increase in levels of NPS treatment 
demand, and there is a lack of national treatment protocols 
and guidelines. Low treatment provision may represent low 
prevalence of NPS use, a low level of problematic use, and/or 
poor identification of use and treatment need (including 
underreporting of NPS use by clients, lack of suitable 
screening instruments and low professional awareness of 
NPS). Results from a French online survey conducted in 2014 
as part of the European project I-TREND showed that the 
occurrence of adverse effects associated with NPS during last 
use concerned approximately 4 out of 10 users (Cadet-Taïrou, 
2016). However, support from a health professional was 
sought by less than 4 % of them. Existing treatment services 
that have traditionally focused on opiate or cocaine users may 
not be orientated towards meeting the real or perceived needs 
of NPS users. In order to address this, new services have been 
developed in several EU countries that specifically respond to 
the needs of new client groups (e.g. MSM, users of club drugs; 
see box on ‘Club Drug Clinic’, p. 17) who are users of NPS and 
other drugs. Although client-level factors may differ between 
countries (e.g. substances used, demographics, rurality and 
access to services), common structural barriers can be 
challenged. These include: ensuring that staff competencies 
are widened to include those skills required to screen, assess 
and treat NPS problems; the provision of support to develop 
topic expertise on NPS (e.g. training on broad classes of 
drugs, effects and harms); the development of cultural 
competencies to work with a wide range of client groups; the 
identification of clear pathways to more specialised support 
for complex cases; and the establishment of ((inter)national) 
networks to share evidence, develop guidelines and facilitate 
professional development (PHE, 2014).
I Low-threshold settings
Low-threshold services provide day-to-day support for 
drug users on a regular basis, and frequently deliver harm 
reduction activities. These services typically require less 
client motivation to attend than structured drug treatment, 
and are often accessible to those individuals and groups 
who may not be willing or able to access more specialised 
services. In addition to providing a range of harm reduction 
activities and some types of prescribing regimes (e.g. 
needle exchange, advice and information, opioid 
substitution treatment), low-threshold services may also 
offer assistance relating to housing, hygiene and sexual 
health (Edland-Gryt and Skatvedt, 2013). These types of 
services proactively contact hidden populations of drug 
users through outreach work, telephone helplines, online 
platforms (see section on ‘Internet and digital devices’, 
p. 20) or co-location with community health services. 
Although by their nature low-threshold services may 
require little or no formal assessment of clients before they 
are allowed to receive support, it is important that the 
nature of the service user’s NPS use and associated 
drug-using behaviour (e.g. injecting) are investigated in 
order to provide appropriate harm reduction advice and, if 
appropriate, referral to more specialised services. Given a 
lack of data on the use, nature, harms and effectiveness of 
low-threshold responses to NPS use, existing effective 
approaches to reducing drug use and associated harms in 
this setting may be adapted to incorporate NPS.
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The NePTuNe guidance material has been developed to 
improve clinical practice in the management of harms 
resulting from the use of club drugs and NPS. it is aimed at 
clinicians working in a range of frontline settings, including 
drug treatment and recovery services, emergency 
departments, sexual health services, primary care and mental 
health services. it aims to improve the confidence, 
competence and skills of clinicians and other professionals in 
the detection, assessment and management of the acute and 
chronic harms associated with the use of club drugs and NPS.
NePTuNe specifically addresses the diverse new 
contexts and patterns of use, risk and harms of club 
drugs (e.g. clubbing, festivals, sexual behaviours).
A number of documents have been developed by 
NePTuNe to support this process:
Guidance on the clinical management of acute and 
chronic harms of club drugs and NPS
This guidance is based on a systematic review and 
critical appraisal of the english language literature. 
Where evidence was lacking, clinical consensus was 
sought from the multidisciplinary group of expert 
advisors to the project.
in order to deal with the ever-growing number of club drugs 
and NPS, NePTuNe adopted the following approach:
QQ Club drugs and NPS are classified based on their 
primary effects as depressants, stimulants and 
hallucinogens. in addition, SCrAs are treated as a 
separate category, largely for reasons relating to their 
availability and clinical management.
QQ The guidance focuses in particular on commonly used 
club drugs and NPS including, but not limited to, gHB, 
ketamine, methamphetamine, mephedrone, MDMA, 
SCrAs and a range of hallucinogens.
The NePTuNe guidance reports using a consistent 
structure as follows:
QQ quality of research evidence;
QQ brief summary of pharmacology;
QQ prevalence and patterns of use;
QQ routes of ingestions and frequency of dosing;
QQ desired effects of recreational use;
QQ acute harms and management of acute harms;
QQ harms from chronic use and management of harms 
from chronic use;
QQ public health and safety, harm reduction and recovery.
E-learning modules and other clinical tools
evidence-based guidance documents are essential but 
not sufficient on their own. NePTuNe translated its 
guidance into tools that are accessible, convenient and 
easy to use for clinicians.
Online modules
in collaboration with the royal College of Psychiatrists, 
NePTuNe is developing a suite of e-learning tools based 
on the College’s experience of developing continuing 
professional development:
Module 1 An introduction to club drugs and NPS
Module 2 Acute harms and management
2a. Depressant and synthetic cannabinoid receptor agonists
2b. Stimulants and hallucinogens
Module 3 Chronic harms and management
3a. Depressant and synthetic cannabinoid receptor agonists
3b. Depressant and synthetic cannabinoid receptor agonists
Clinical tools
Care bundles are being developed relating to the clinical 
management of the harms of some club drugs and NPS. 
These are algorithms or tick list that provide a structured way 
of improving the processes of reliable care. They are a small, 
straightforward set of evidence-based practices that, when 
performed collectively and reliably, improve outcomes.
See: www.neptune-clinical-guidance.co.uk
NEPTUNE guidelines, United Kingdom
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In general, low-threshold and harm reduction activities for 
NPS will mirror those delivered to users of established 
drugs but there are additional considerations with respect 
to injection. Injectors of NPS may be at increased risk of 
harm due to exposure to novel drugs with uncertain 
psychopharmacological and toxicological profiles. For 
example, the injection of stimulant NPS such as the 
synthetic cathinone mephedrone among some existing 
opioid injectors and drug treatment clients has been 
reported in a number of European countries (EMCDDA, 
2015b, 2015 d, 2015e; Van Hout and Bingham, 2012). This 
may have led to an increase in the demand for treatment in 
countries such as the United Kingdom (Wales and 
Scotland), Ireland, Hungary and Romania (EMCDDA, 
2015b, 2015d; Van Hout and Bingham, 2012). There have 
also been reports in several EU countries of injection site 
bacterial infections and tissue damage, transmission of 
blood-borne viruses (HIV, HCV) and increased injection 
risk (e.g. rapid transition between injection of different 
NPS, sharing equipment, sexual risk-taking, increased 
injection frequency and initiation of NPS injection) 
associated with the injection of NPS (Botescu et al., 2012; 
EMCDDA, 2015b, 2015d, 2015e; Giese et al., 2015; Karila, 
2015; PHE, 2015; Rácz et al., 2015; , Sande, 2016; Scottish 
Drugs Forum and NHS Lothian, 2015; Van Hout and 
Bingham, 2012, Gyarmathy and Sárosi, 2015). Although 
NPS injection may largely be a localised phenomenon, 
there is emerging evidence that these behaviours have 
become embedded in cohorts in some EU countries 
(Péterfi et al., 2014).
Whilst most NPS injectors are thought to have a history of 
opiate or amphetamine injection and therefore may 
already possess some harm reduction knowledge, it 
should not be assumed that this is sufficient to protect 
against novel harms associated with injecting NPS. 
Although evidence is lacking of the effectiveness of harm 
reduction approaches such as needle and syringe 
exchanges in reducing risky injecting and infections in NPS 
users, the provision of sterile injection equipment/kits and 
condoms and the dissemination of information on safe 
The Club Drug Clinic was established in London in 
2010 and targets users of club drugs (e.g. MDMA, 
methamphetamine, gHB/gBL, ketamine, NPS) who do 
not fit the profile of ‘typical’ drug treatment clients, or 
who do not readily present to traditional drug services. 
in addition to providing a community-based outpatient 
and drop-in service, the Clinic undertakes engagement 
activities online, and in universities, clubs, sexual 
health clinics, mental health treatment settings, 
hospital emergency rooms and prisons. The Clinic 
operates a well-networked multidisciplinary team, and 
although it offers traditional intervention approaches 
for drug-related problems, including relapse 
prevention, it has also developed the skills and cultural 
competencies required to respond to new drug issues 
and reach new client groups. For example, the clinic 
offers a detoxification programme for gHB/gBL; 
manages drug-related comorbidities such as (acute) 
psychotic states associated with the use of synthetic 
cannabinoid receptor agonists; and has developed 
specialisms in relation to chemsex, and hallucinogen 
and ketamine use.
See: clubdrugclinic.cnwl.nhs.uk
Club Drug Clinic, United Kingdom
Novadic-Kentron (NK) is an addiction treatment 
institute in North Brabant, the Netherlands, with 
professional multidisciplinary teams that provide 
outpatient and inpatient treatment services to about 
10 000 clients annually. in addition to detoxification 
treatment, psychiatric and psychological counselling 
and harm reduction, NK also provides prevention and 
awareness programmes addressing both substance 
and behavioural addiction in different settings such as 
schools, clubs, residential areas and prisons. NK treats 
addiction using a mental illness approach according to 
the bio-psychosocial model. This principle is expressed 
in a Community reinforcement Approach treatment 
vision and elaborated in different evidence-based 
medicine care programmes. This approach is 
reinforced by the latest available knowledge and NK’s 
own research results, which include new treatment 
approaches for gambling, internet addiction and 
effective detoxification and treatment of gHB/gBL 
addiction. The detoxification programme is provided by 
means of titration and tapering of pharmaceutical gHB 
in an average period of 10 days. The gHB detoxification 
procedure follows the standardised practice-based 
protocol by Kamal et al. (2013). This detoxification 
approach has been provided to almost 800 clients with 
satisfactory results and has been implemented 
nationally in general hospitals (emergency rooms) and 
mental health and addiction care institutes.
See: www.novadic-kentron.nl
GHB treatment at the Novadic-Kentron 
institute, the Netherlands
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injecting among NPS injectors are important (EMCDDA, 
2016a). However, needle and syringe exchange 
programmes need to adapt to the differing injection 
practices of stimulant injectors (e.g. higher frequency 
injecting). For example, the Alternatíva Foundation in 
Hungary provides a range of low-threshold harm reduction 
services in response to evidence of increasing numbers of 
users injecting NPS (Csák, 2015).
Although their effectiveness has not been assessed, a 
number of outreach approaches such as the provision of 
sterile injection equipment and the dissemination of 
information on proper injection techniques (e.g. the use of 
antibacterial creams and ointments, the rotation of injection 
sites, basic hygiene, vein and wound care) are useful in 
responding to injection site infections among simulant 
injectors (EMCDDA, 2016a). There is also evidence that 
opioid substitution treatment and needle exchange 
programmes are effective for opioid injectors (who may also 
be injecting NPS) in reducing risky drug-taking behaviours 
and mortality, and in preventing infections such as HIV and 
HCV (EMCDDA, 2016a). The detection of blood-borne 
viruses through proactive dried blood spot testing is also in 
place in a number of settings such as low-threshold drug 
services and homeless centres (EMCDDA 2015d; Scottish 
Drugs Forum and NHS Lothian, 2015; Scottish Drugs Forum 
and NHS Greater Glasgow and Clyde, 2015).
Peer educator schemes offer a flexible approach to 
changes in the drug situation, user groups and the drug 
market and have a high potential for delivering individually 
adapted messages and support, which could be an 
important element of the response to NPS.
One example where specific low-threshold staff 
competence is already used to reduce NPS-related harm is 
the Local PASS project. Here, peers and (other) low-
threshold staff collaborate as partners of a Local Emerging 
Drug Trend Panel in identifying new substances, risk 
groups and settings and by grading the risks. The Panel 
then takes a decision about the relevant interventions, 
according to type and risk level (www.localpass.eu/cms/
local-pass-toolkit).
Furthermore, the supervised drug consumption facilities in 
58 European cities have the potential to become ‘early 
warning’ sites for collecting samples of novel substances 
(and through an analysis of the residual content of used 
syringes returned to the services), in order to analyse their 
composition and potency so that relevant risk information 
can be transmitted to drug users. Important progress could 
be made in consumer protection by making information on 
drug composition rapidly available to users. Drug 
consumption spaces also provide a ‘learning environment’ 
where staff can assess NPS risk behaviours and harms, and 
develop ways to transmit ‘safer use’ messages.
In the United Kingdom, NPS injection and associated 
harms have been responded to by revising surveillance 
systems for BBV infection among PWID and by developing 
proactive community outreach for individuals not in 
contact with services such as needle and syringe 
programmes (PHE, 2015). Increasing the accessibility and 
provision of sterile injecting equipment and the 
opportunity for BBV testing in specialist services and 
community environments has been prioritised, as has 
raising awareness of the risks of injection, particularly 
co-infection with HIV (PHE, 2015). Published guidelines 
also present generic injection harm/risk reduction advice, 
but include specific items on dose titration, the use of 
solvents such as citric acid and alternative administration 
routes (NHS Greater Glasgow and Clyde and Scottish 
Drugs Forum, 2014).
I Prisons and custodial settings
People in prison are a high-risk group for drug use and 
report higher lifetime rates and more harmful patterns of 
use than the general population (EMCDDA, 2015b). Illicit 
drugs are widely available within prisons, and some 
individuals continue or even initiate use during 
incarceration (EMCDDA, 2015b). Dual diagnosis of 
psychopathology and the coexistence of complex needs 
are commonly reported among the drug-using prison 
population (Department of Health, 2009). People in prison 
Crew2000 is a sexual health and drug service that 
provides a range of low-threshold harm reduction 
services to users of both established and new drugs, 
delivered by a diverse team of staff including peer 
workers. it is an example of a low-threshold service 
offering a comprehensive package of services that have 
been adapted to respond to NPS. Services include the 
provision of information and advice via telephone 
helplines and drop-in, outreach (including crisis work at 
festivals — see p. 9 for further information on nightlife 
responses to NPS), counselling, self-assessment, 
complementary therapies, recovery support, training 
and school curriculum development around NPS 
(Crawshaw, 2015).
See: www.crew2000.org.uk
Crew 2000, Scotland
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are also a high-risk group for NPS use (DrugScope, 2015; 
Abdulrahim and Bowden-Jones, 2015), yet there remains a 
lack of evidence on the scale, nature and harms associated 
with NPS use in European prisons. Furthermore, it was 
only possible to identify specialist guidance from the 
United Kingdom for this report.
The data on NPS use in prisons and custodial settings in 
Europe is scarce. Data on the use of NPS among inmates in 
Portugal revealed a prevalence of use of 4.1 % ever in life 
and 1.6 % during imprisonment (Torres et al. 2015), while a 
Hungarian study showed the most frequently reported NPS 
was mephedrone, which had been used by 12.6 % of 
inmates at least once in their life (Ritter, 2013). Similarly, a 
Latvian study showed that one in four inmates (25 %) had 
used an NPS at some point in their life; in 92 % of the cases 
herbal smoking blends (such as Spice) had been used 
(Kļave et al., 2014). Expert opinion from countries such as 
Germany, the Netherlands and the United Kingdom 
suggests NPS such as pregabalin and GHB are being used 
in prison (ACMD, 2016; Montanari and Royuela, 2015). In 
the United Kingdom the use of SCRAs in particular is on the 
increase in prisons (particularly men’s prisons) (Centre for 
Social Justice, 2015; HM Inspectorate of Prisons, 2015a; 
RAPt, 2015; Abdulrahim and Bowden-Jones, 2015; PHE, 
2015). For example, the number of UK prison seizures of 
these substances increased from 10 in 2010 to 737 in 2014 
(DrugScope, 2015; PHE, 2015; Centre for Social Justice, 
2015). Recent estimates from the United Kingdom 
suggested that 6 % of people in prison reported using the 
SCRAs Spice/Black Mamba before incarceration and 10 % 
whilst in prison, making it the second most commonly 
reported drug used in prisons (after cannabis at 13 %) (HM 
Inspectorate of Prisons, 2015b; PHE, 2015). 
Hospitalisations, seizures, psychotic episodes, violence, 
debt, bullying and intimidation have all been recorded as 
being associated with the use and distribution of such 
substances (Brown and Thomas, 2015; Prisons and 
Probation Ombudsman, 2015a, 2015b; RAPt, 2015; HM 
Inspectorate of Prisons, 2015b; PHE, 2015). Moreover, 
between 2012 and 2014 a total of 19 suspected NPS-
associated deaths were recorded in UK prisons (Prisons and 
Probation Ombudsman, 2015a, 2015b). Overall, there is a 
lack of formal research on this topic across Europe and 
available information still comes from anecdotal reports.
The use of NPS in custodial settings presents challenges 
to healthcare and to prison staff, who may find it difficult to 
work with individuals with complex needs and help them 
engage with substance use and mental health teams 
(PHE, 2015). A range of responses have been implemented 
in UK prisons, but these responses have tended to be 
regulatory, addressing supply, and rely on punitive actions 
including adjudications and loss of privileges through the 
use of drug detection dogs and targeted searching 
(Ministry of Justice, 2015; HM Inspectorate of Prisons, 
2015a, 2015b). New legislation in the United Kingdom 
(Psychoactive Substances Act 2016) also allows for 
additional custodial time for individuals found guilty of 
NPS possession and supply offences in prisons (Home 
Office, 2015). Difficulties in the forensic and toxicological 
testing of most NPS make their monitoring and regulation 
difficult (Centre for Social Justice, 2015; RAPt, 2015; HM 
Inspectorate of Prisons, 2015a) and may contribute to 
inmates’ interest in using these substances.
Health and intervention responses have begun to emerge 
in some UK prisons, but provision remains limited. NPS 
professional leads have been introduced in some prisons 
to develop strategies to respond to NPS use, and NPS 
working groups involving prison management, healthcare 
and substance misuse teams have been established to 
share knowledge and experiences, and encourage 
collaborative working (RAPt, 2015). There have also been 
some communication and awareness actions around NPS 
within prisons that aim to inform individuals in prison, staff 
and visitors about the risks of NPS, but there is no 
information on the nature and effectiveness of these 
activities (Prisons and Probation Ombudsman, 2015a, 
2015b; RAPt, 2015). See box on p. 20 for a summary of UK 
guidance on responding to NPS in prisons.
With a lack of data on the use, nature, harms and 
effectiveness of responses to NPS use among the prison 
population, existing effective approaches in reducing drug 
use and associated harms for this population may be 
adapted to incorporate NPS. For NPS users who may also 
be using opioids and injecting NPS, evidence supports the 
use of opioid substitution treatment to reduce mortality 
and risky drug-injecting behaviours in prison and continuity 
in treatment when reintegrated back into the community 
(EMCDDA, 2016c). Moreover, psychosocial treatment has 
been found to be effective in reducing re-incarceration 
(EMCDDA, 2016c). High rates of injecting drug use, HCV 
and other infectious diseases are also found among the 
prison population which means health assessment upon 
prison entry is an important intervention (EMCDDA, 
2015b). The provision of clean needles and syringes is 
important for those who may be injecting NPS or for users 
of NPS who may be injecting other drugs. However, it 
remains unclear whether such responses help to prevent 
risky practices and infectious diseases in prison 
(EMCDDA, 2016c). Interagency partnerships between 
prison health services and providers in the community are 
also important in delivering health education and 
treatment interventions in prison and in ensuring 
continuity of care upon prison entry and release 
(EMCDDA, 2014d, 2015c).
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I  Internet and digital devices as platforms for the delivery of health responses and interventions
In recent years the internet and other digital platforms 
such as smart phone apps have become more popular as a 
means of delivering health interventions. Although 
evidence on the effectiveness of these approaches in 
general is currently limited (e.g. Free et al., 2013), 
substance use and sexual health services across Europe 
have begun to use technology as an extension of existing 
communication platforms for responding to substance use 
and related harms. Such platforms are additional 
opportunities for the provision of drugs information, and 
for prevention programmes, outreach services and 
treatment programmes (EMCDDA, 2015b; ECDC, 2015). 
They also allow for anonymity when accessing information 
or seeking one-on-one help from health professionals, 
provide ease of access (for some) and allow messages to 
be tailored to individuals (Champion et al., 2015). Given 
increases in internet access and the significant role the 
internet plays in the supply and sale of NPS, providing 
information and opportunities for prevention and 
intervention online seems an appropriate response for 
particular user groups.
Whilst some services have relocated health and 
intervention responses to virtual spaces to increase their 
accessibility to new and existing target groups (EMCDDA, 
2015b), it is important to acknowledge that due to 
structural barriers (such as digital divides) some groups 
(e.g. homeless, people in prison, PWID) may not have 
adequate access to such devices. Therefore, while internet 
and digital platforms may provide an important additional 
opportunity to engage and target some groups they should 
not replace existing platforms without due consideration.
There is currently no evidence upon which to make 
recommendations for specific NPS-based online 
prevention and intervention responses, yet there are 
examples of services using these platforms to reach, 
engage and inform users. These include drug user-led 
initiatives providing NPS advice and information, which in 
QQ The prevalence of NPS use, effects and harms should 
be estimated within prison establishments and used 
to inform appropriate responses.
QQ integrated and joined-up approaches involving 
custodial, health and psychosocial staff should be 
established.
QQ Staff within prison healthcare services should hold 
core drug-related professional competences that 
enable them to be confident in dealing with individual 
users and in providing advice and treatment related to 
the main NPS groups. They should be trained and 
supported in recognising and managing the effects of 
NPS, or the effects of combining NPS with other drugs 
or prescribed medication.
QQ  NPS awareness and training sessions should be 
delivered to inmates, including information on safer 
use, NPS interaction with prescribed medication and 
other illicit drugs, and what action should be taken in 
an emergency.
QQ Suitable interventions to support and treat people 
who have developed NPS problems should be made 
available. Personalised and responsive care and the 
adaption of current approaches for existing drugs 
should be provided. 
QQ Harm reduction advice and appropriate psychosocial 
interventions should be available to individuals whose 
NPS use is identified as being problematic.
QQ Clinical guidance (such as the NePTuNe guidelines, 
see box on p. 16) should be referred to in the 
treatment of NPS use.
QQ responses should be guided by evidence and advice 
from national poisons information services that aims 
to support the management of people admitted to 
hospitals with exposure to suspected poisons (see 
box on ‘National Poisons information Service’, p. 13).
QQ A threshold for calling for an ambulance and/or 
sending an affected individual to hospital should be 
in place.
QQ Debt and bullying should be responded to by 
investigating incidents, challenging perpetrators and 
providing individualised long-term solutions, with 
support and protection for victims and consideration 
of the impact of NPS-related bullying on the risk of 
suicide and self-harm.
(1) PHe, 2014, 2015; Prisons and Probation Ombudsman, 2015a, 2015b
Published guidance for responding to NPS use in prisons (1) 
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some cases incorporate drug-testing/drug-checking 
services that disseminate test results and harm reduction 
messages online (e.g. DIMS, WEDINOS, see drug checking 
in section ‘Nightlife settings’). For example, DrugLijn in 
Belgium provides confidential non-judgemental 
information and advice (e.g. effects, risks, harm reduction), 
counselling and referral for a number of substances, 
including NPS, to the public anonymously via the internet 
(email, one-on-one chat, Skype) and via more traditional 
telephone helplines. The project also plays a role in 
monitoring NPS use by reporting new substances or new 
substance use behaviours to the EU Early Warning System 
via the Belgian Reitox national focal point. It also provides 
online early intervention tools such as knowledge tests, 
self-assessment questionnaires and online self-help 
modules. Advice on NPS is requested by users accessing 
the service at lower rates than other substances, but a 
variety of NPS-related advice is still sought, including 
information on legal status, complications following use, 
short- and long-term effects and information on the 
detection of NPS substances in blood and urine testing 
(Evenepoel, 2015).
The internet and digital applications are also being used by 
sexual health services in countries such as  France and the 
United Kingdom (e.g. 56 Dean Street, see box on p. 11) to 
engage MSM who participate in chemsex, in sexual health 
and substance use services. Although the provision of 
information may increase knowledge of drug-related 
harms, such approaches must be careful not to normalise 
use or harmful behaviours (Brewer, 2003).
The impact and effectiveness of internet and digital 
approaches in targeting, engaging and changing behaviour 
in NPS users is unknown. To date there are no published 
evaluations of intervention and prevention programmes 
specifically for NPS that include internet-based 
approaches (Champion et al., 2015). However, the Climate 
Schools: Ecstasy and Emerging Drugs Module based in 
Australia is the first example of an internet-facilitated 
universal school-based prevention programme aimed at 
addressing the use of both ecstasy and NPS among 15- to 
16-year-olds. This programme has previously been shown 
to be effective in reducing alcohol, tobacco and cannabis 
use among young people, and the model has been 
extended and applied to the prevention of NPS use among 
this cohort. However, the programme is currently being 
trialled and so cannot yet be recommended (Champion et 
al., 2013, 2015).
I Conclusion
The NPS market is complex and the rapid emergence of 
novel products means that developing supportive health 
intervention responses is challenging. The significant 
annual number of detections of new NPS by the EU Early 
Warning System may suggest that services for users need 
to be continually developed. However, whilst there is the 
risk that new products with unpredictable toxic profiles 
may enter the market and it is important to regularly 
update knowledge and skills around the needs of NPS 
users, existing research evidence (albeit limited in nature), 
expert opinion and guidelines suggest that it is possible to 
develop and deliver a comprehensive health response to 
the harms associated with NPS use.
Limited experience and evidence in responding to/
managing NPS-related chaotic use and the diagnosis and 
prognosis of acute somatic harms due to NPS can at times 
make it difficult to distinguish between occasional 
problematic use and a more entrenched drug problem. It is 
important to acknowledge that the problematic use is not 
necessarily defined by the NPS in itself but rather by the 
intensity of use, and that there is a risk of labelling singular 
adverse events as an entrenched and persistent drug 
problem. Thus, acute healthcare management (e.g. within 
emergency settings) and brief interventions may be 
sufficient for experimental or occasional users 
experiencing an acute adverse event. Consumer protection 
actions such as drug checking and harm reduction 
interventions provide opportunities to reduce and prevent 
such harmful events for recreational or occasional users. 
Long-term problematic use, on the other hand, requires 
proper clinical assessment and care, as with any other 
problematic drug use and/or drug dependence.
Thus, the approaches identified and recommended in this 
report are largely based upon existing responses to drug 
use. These approaches have been adapted to ensure that 
they reflect: unique user group needs; the structural, 
cultural and social contexts of use; new opportunities for 
engaging with user groups and service delivery; and the 
need to develop specific cultural competencies among 
people delivering such services. However, it is important to 
acknowledge that existing prevention, treatment and harm 
reduction responses to drug use still often lack strong 
evidence of effectiveness. Therefore, the adaption of these 
interventions to respond to NPS must proceed with 
caution and within a robust evaluative framework. 
Although this report has focused on a limited number of 
selected settings and responses, it is likely that other 
existing types of interventions for drug use may be 
successfully adapted for NPS-using groups. However, 
although innovation should be encouraged, adaption 
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should always be carefully managed, monitored and 
evaluated; and approaches that have already been shown 
to be ineffective or unhelpful are unlikely to be improved 
with adaption.
In addition to the specific recommendations included in 
this report, the following general recommendations should 
be considered:
QQ Professionals’ lack of experience with NPS and lack of 
knowledge of their pharmacology does not mean that 
they do not have the skills to support the users of these 
drugs. A professionally competent workforce is likely to 
already possess the skills required to support health 
responses to NPS use.
QQ Whilst some (new) specialism is needed in some types 
of response (e.g. GHB detox, supporting chemsex 
participants), approaches to NPS should be based on 
existing guidelines and evidence-based approaches. 
Where adaption is required, this should be based upon 
responding to the specific needs of the target population, 
and/or the emergence of new types of behaviour (e.g. 
NPS injection). However, this assumes that existing 
responses to drug use are already effective and delivered 
to a high standard; it is clear that this is not always the 
case and practitioners should therefore rely on the best 
available evidence as recommended in existing 
evidence-based guidelines.
QQ Multidisciplinary approaches that respond to health 
needs as part of a broader approach may be useful (e.g. 
chemsex). Joined-up working across services is 
considered important, but this is often very difficult to 
realise.
QQ Professional networking is important, but there are 
limitations with regard to the transferability and 
generalisability of approaches across borders, under 
different policy constraints and with respect to different 
user behaviours and characteristics.
QQ Cultural competence, and the understanding of how 
(sub-)cultural issues influence patterns of drug use and 
associated problems, is likely to improve service 
engagement and uptake. Services must be accessible 
and welcoming, and staff may require training to develop 
the necessary cultural competencies to work with 
diverse groups of NPS users.
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Novel Substances Project) (www.wedinos.org)
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level. 
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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